Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib with or without dose titration in EGFR+ NSCLC
NCT04027647Phase 2Active, not recruiting
- Sponsor
- National Cancer Centre Singapore
- Start
- Sep 2019
- Primary completion
- Mar 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 5
01
Overview
A Phase 2 trial of dacomitinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Centre Singapore. Started Sep 2019; status: active, not recruiting.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04027647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04027647.